(Q43106531)

14 November 2017

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease (English)

1 reference

14 November 2017

1 reference

1 reference

E Terpos

1

1 reference

14 November 2017

J Berenson

2

1 reference

14 November 2017

R J Cook

3

1 reference

14 November 2017

A Lipton

4

1 reference

14 November 2017

R E Coleman

5

1 reference

14 November 2017

8 April 2010

1 reference

14 November 2017

1 reference

14 November 2017

24

1 reference

14 November 2017

5

1 reference

14 November 2017

1043-1049

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2010.62

14 November 2017

0 references

cites work

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

inferred from DOI database lookup

7 January 2021

based on heuristic

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.62

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.62

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference